ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
Wet Age-Related Macular Degeneration (wet AMD)
Key Facts
About Outlook Therapeutics
Outlook Therapeutics is a late-stage biopharma company with a mission to commercialize the first approved ophthalmic bevacizumab, LYTENAVA™, to replace the risky, off-label use of repackaged Avastin® in ophthalmology. The company has achieved its first major regulatory success with marketing authorization in the EU and UK, has commenced launch in Germany and the UK, and has resubmitted its BLA to the FDA for a potential U.S. approval. Its strategy hinges on capturing a significant portion of the large, cost-sensitive anti-VEGF market by offering a lower-cost, approved alternative to existing branded therapies.
View full company profileAbout Outlook Therapeutics
Outlook Therapeutics is a late-stage biopharma company with a mission to commercialize the first approved ophthalmic bevacizumab, LYTENAVA™, to replace the risky, off-label use of repackaged Avastin® in ophthalmology. The company has achieved its first major regulatory success with marketing authorization in the EU and UK, has commenced launch in Germany and the UK, and has resubmitted its BLA to the FDA for a potential U.S. approval. Its strategy hinges on capturing a significant portion of the large, cost-sensitive anti-VEGF market by offering a lower-cost, approved alternative to existing branded therapies.
View full company profileAbout Outlook Therapeutics
Outlook Therapeutics is a late-stage biopharma company with a mission to commercialize the first approved ophthalmic bevacizumab, LYTENAVA™, to replace the risky, off-label use of repackaged Avastin® in ophthalmology. The company has achieved its first major regulatory success with marketing authorization in the EU and UK, has commenced launch in Germany and the UK, and has resubmitted its BLA to the FDA for a potential U.S. approval. Its strategy hinges on capturing a significant portion of the large, cost-sensitive anti-VEGF market by offering a lower-cost, approved alternative to existing branded therapies.
View full company profile